Previous 10 | Next 10 |
Tuesday was a bad day on Wall Street, as investors reacted negatively to new tariffs that went into effect between the U.S. and China. Many market participants had hoped that the two parties would agree to some kind of temporary reprieve to avoid the uptick in trade tensions, but it now appears ...
When pharmaceutical companies manage to get highly positive results from clinical trials of one of their more important products, then it almost always has a positive impact on the stock price, and that is what happened with MDCO stock. Solid Boost The Medicines Company (NASDAQ:MDCO) an...
Gainers: Abeona Therapeutics (NASDAQ: ABEO ) +79% . Cidara Therapeutics (NASDAQ: CDTX ) +56% . Ardelyx (NASDAQ: ARDX ) +33% . Quorum Health Corporation (NYSE: QHC ) +21% . Net Element (NASDAQ: NETE ) +19% . Conn's (NASDAQ: CONN ) +18% . Cassava Sciences (NASDAQ: SAVA ) +15% . ...
The Medicines Company (NASDAQ: MDCO ) is up 17% premarket on light volume in response to its announcement of positive results from a Phase 3 clinical trial, ORION-11 , evaluating inclisiran, administered twice per year, for lowering "bad" cholesterol (LDL-C) in patients with a...
- Inclisiran achieved 54% LDL-C lowering with time-adjusted reductions of 50% sustained over 18 months of treatment - ORION-11 study demonstrates inclisiran’s excellent safety profile, including no treatment-related liver or renal abnormalities - Full study res...
The Medicines Co. ( MDCO ) announced that it had achieved the primary and key secondary endpoints for its late-stage study using inclisiran to treat patients with atherosclerotic cardiovascular disease ((ASCVD)) or ASCVD-risk equivalents along with elevated bad cholesterol despite maximu...
Back in May, Esperion Therapeutics ( ESPR ) announced the FDA set two PDUFA dates in February for the company's two leading products, bempedoic acid and bempedoic acid/ezetimibe combination tablet. Both of these product candidates are looking to be approved to treat elevated low-density lipo...
Shares of The Medicines Company (NASDAQ: MDCO) jumped 13.8% on Monday after the biotech announced that Orion-11, a clinical trial testing inclisiran in patients with high levels of LDL cholesterol, was successful. Interestingly, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) , w...
Arcadia Biosciences (NASDAQ: RKDA ) +21% on high fiber wheat deal . More news on: Arcadia Biosciences, Inc., The Medicines Company, Pitney Bowes Inc., Stocks on the move, Read more ...
The Medicines Company (NASDAQ: MDCO ) announces positive results from a Phase 3 clinical trial, ORION-11 , evaluating twice-yearly dosing of inclisiran aimed at reducing LDL-C ("bad" cholesterol) in patients with atherosclerotic cardiovascular disease. More news on: The Medicines Compan...
News, Short Squeeze, Breakout and More Instantly...
The Medicines Company Company Name:
MDCO Stock Symbol:
NASDAQ Market:
The Medicines Company Website:
The Medicines Company (the “Company”) today provided notice of a Make-Whole Fundamental Change to holders of its (i) 2.50% Convertible Senior Notes due 2022 (the “2022 Notes”), (ii) 2.75% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 3...
Shares of Meritor (NYSE: MTOR) , a global supplier of drivetrain, braking, and other aftermarket automotive solutions for vehicles, jumped as high as 16% Tuesday morning after markets digested the announcement that Meritor will join the S&P SmallCap 600 index. The announcement actually c...
NEW YORK , Dec. 30, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600 effective prior to the open of trading on Monday, January 6 : NexPoint Residential Trust Inc. (NYSE: NXRT) will replace Avon Products Inc. (NYSE: AVP). Natura...